NCT00869232View on ClinicalTrials.gov

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Velcade

1.0mg/m2 days 1, 5, 8, \& 11

DRUG

Melphalan

10 mg/m2 day 3

DRUG

Thalidomide

200 mg days 5-8

DRUG

Dexamethasone

40 mg day 5-8

DRUG

Cisplatin

10 mg/m2 day 5-8

DRUG

Adriamycin

10 mg/m2 day 5-8

DRUG

Cyclophosphamide

400 mg/m2 day 5-8

DRUG

Etoposide

40 mg/m2 day 5-8

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER